title: Prostate cancer: What is the optimal treatment sequence for mCRPC?
authors: Departments of Medicine and Urology, Tulane University School of Medicine, Box SL 42, 1430 Tulane Avenue, New Orleans, Louisiana 70112-2699, USA.
authors: Oliver
authors: O
authors: Sartor
mesh_terms: D000736:Androstenes / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D017326:Clinical Trials, Phase III as Topic / Q000379:methods; D006801:Humans; D008297:Male; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D064129:Prostatic Neoplasms, Castration-Resistant / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000736:Androstenes; D000970:Antineoplastic Agents; D001549:Benzamides; D009570:Nitriles; D010669:Phenylthiohydantoin; C540278:enzalutamide; C089740:abiraterone